Phase 3 data is still away. What we are expecting is approx timeline for the completion of enrollment of 300 patients in adjunct therapy - as per original estimates it was supposed to be completed by Aug 2016. The PR will give the revised dates.
IMO the possible SP movers are the following
1. Jun ASMMICROBE presentation - the results are already known (they may add few other test results) but being presented in scientific conf and in front of peers will give it much credibility and visibility. It will get scientific exposure which could bring more investors
2. If the expected enrollment completion is earlier than Aug 2016
3. The primary endpoint for P3 - the primary endpoint can be known in 2 weeks of last patient enrollment - this will show viral load suppression after 1 week - although the actual trial will last for 24 more weeks from last patient, the 1 week result will show efficacy and drive SP
4. Unexpected partnership based on interim progress
News 
Market Data 
Discover 
AI
